BGSF, Inc. Becomes a Workday Deployment Partner
PLANO, Texas--(BUSINESS WIRE)--BGSF, Inc. (NYSE: BGSF), a growing provider of consulting, managed services, and professional workforce solutions, announced today that it has become a Workday Deployment Partner. This new designation further solidifies BGSF's trusted Workday Services Partner role, enhancing its ability to deliver top-tier talent and comprehensive support to Workday customers nationwide. Workday is the AI platform for managing people, money, and agents.
BGSF has served as a Workday Services Partner for almost two years. With a deep understanding of the Workday platform, BGSF has consistently provided exceptional consultants and workforce solutions tailored to clients' evolving needs. BGSF will now offer expanded support, including:
Feature Adoption & Optimization – Helping organizations leverage the latest Workday updates to maximize efficiency.
Business Transformation – Providing strategic guidance and staffing solutions to navigate complex digital transformations.
Staff Augmentation & Permanent Placement – Connecting clients with experienced Workday professionals to fill critical roles.
Post-Production Support & Phase X Projects – Delivering ongoing assistance to ensure continued success with Workday's ecosystem.
'As organizations continue to evolve in today's dynamic digital environment, the demand for seamless and impactful Workday solutions has never been greater,' said Beth Garvey, Chair, President, and CEO of BGSF. 'Becoming a Workday Deployment Partner is a tremendous milestone for us—it not only deepens our commitment to delivering expert talent and strategic support, but also reflects our gratitude for the trust and collaboration we've built with Workday. We're excited to take this next step with Workday.'
BGSF's Workday-focused consultants bring in-depth expertise across various industries, enabling clients to streamline operations, enhance system functionality, and drive business results. The company's proven track record in workforce solutions and consulting services positions it as a valuable partner for organizations undertaking new Workday deployments and seeking both the right talent and implementation expertise.
About BGSF
BGSF provides consulting, managed services and professional workforce solutions to a variety of industries through its various divisions in IT, Finance & Accounting, Managed Solutions, and Property Management. BGSF has integrated several regional and national brands achieving scalable growth. The Company was ranked by Staffing Industry Analysts as the 97th largest U.S. staffing company and the 49th largest IT staffing firm in 2024. The Company's disciplined acquisition philosophy, which builds value through both financial growth and the retention of unique and dedicated talent within BGSF's family of companies, has resulted in a seasoned management team with strong tenure and the ability to offer exceptional service to our field talent and client partners while building value for investors. For more information on the Company and its services, please visit its website at www.bgsf.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
ARK Invest Offloads Over $50M in Circle Shares as Stock Extends Rally
Cathie Wood's ARK Invest trimmed its holdings on its sizable Circle (CRCL) position Monday, selling $51.8 million worth of shares, as the stablecoin issuer's stock extended its rally. ARK sold a total of 342,658 shares across three of its actively managed exchange-traded funds (ETFs), according to a daily email. The ARK Innovation ETF (ARKK) offloaded 196,367 shares, ARKW sold 92,310 and ARKF trimmed 53,981. Circle, the issuer of the USDC stablecoin, rose 13% on the day, closing Monday in New York at $151.06. It has gained every day but two since it listed on June 5. The shares have climbed almost fivefold from their IPO price of $31. ARK bought $373 million worth of Circle on its first day of trading on the NYSE. Wood's fund also recently trimmed positions in other crypto-linked firms like Coinbase (COIN) and Robinhood (HOOD). Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Skyhawk Therapeutics Announces First Patient Dosed in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntington's Disease
SKY-0515 is an oral small molecule designed to reduce the production of both huntingtin (HTT) and PMS1 proteins—two key drivers of HD pathology Initiation of the FALCON-HD trial follows promising Phase 1 results demonstrating up to 72% reduction in HTT mRNA in healthy volunteers The SKY-0515 Phase 1 trial in patients with Huntington's disease reached full enrollment ahead of schedule BOSTON, June 18, 2025 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today announced that the first patient has been dosed in its Phase 2/3 FALCON-HD trial evaluating SKY-0515, an investigational oral RNA splicing modulator for the treatment of Huntington's disease (HD). SKY-0515 is designed to reduce the production of both HTT and PMS1 proteins—two key drivers of HD pathology. In a Phase 1 study in healthy volunteers, SKY-0515 demonstrated dose-dependent HTT mRNA reduction, achieving an average of 72% lowering at the highest dose tested. The compound was generally well tolerated across all doses. Additionally, the Company's Phase 1 trial in HD patients, which began in January 2025, completed enrollment ahead of schedule in March 2025. "Dosing the first patient in our FALCON-HD trial marks a significant milestone in our mission to develop a disease-modifying therapy for Huntington's patients," said Bill Haney, Founder and Chief Executive Officer of Skyhawk Therapeutics. "Building on our compelling Phase 1 data, we are eager to assess SKY-0515's potential to make a meaningful difference in the lives of patients affected by this devastating condition." FALCON-HD is a Phase 2/3 randomized, double-blind, placebo-controlled, dose ranging study to evaluate the pharmacodynamics, safety, and efficacy of SKY-0515 in participants with Stage 2 and early Stage 3 HD. The trial includes multiple sites across Australia and New Zealand. The initial dosing took place at Flinders Medical Centre in Adelaide, Australia. "We are pleased to participate in this important clinical trial and to have dosed the first patient here at Flinders," said Dr. Karyn Boundy, FRACP, Neurologist, Principal Investigator at Flinders Medical Centre. "Given the lack of approved disease-modifying treatments for Huntington's disease, we are hopeful that SKY-0515 could offer a new therapeutic option for patients." "As Skyhawk kicks off their Phase 2/3 FALCON-HD trial in Australia and New Zealand, the international Huntington's community looks forward to expansion worldwide," said Ed Wild, professor of neurology at the University College London. "SKY-0515's unique ability to reduce both HTT and PMS1 could meaningfully enhance therapeutic impact beyond that of lowering HTT alone." About the FALCON-HD TrialFALCON-HD (NCT06873334) is a Phase 2/3 randomized, double-blind, placebo-controlled, dose ranging study to evaluate the pharmacodynamics, safety, and efficacy of SKY-0515 in participants with Stage 2 and early Stage 3 HD. The trial plans to enroll 120 subjects across 10 sites in Australia and New Zealand. Eligible patients will receive a once-daily oral dose of SKY-0515 at one of three dose levels, or placebo, for a treatment period of at least 12 months. The trial aims to assess the potential of SKY-0515 to modulate RNA splicing and reduce the production of huntingtin (HTT) and PMS1 proteins, which are implicated in the pathology of Huntington's disease. Additional information about FALCON-HD, including participating sites and eligibility criteria, can be found at and About SKY-0515SKY-0515 is an orally administered small molecule RNA splicing modulator developed through Skyhawk's proprietary platform. It is designed to reduce production of both huntingtin (HTT) and PMS1 proteins, two key contributors to Huntington's disease. SKY-0515 has shown robust, dose-dependent HTT mRNA reduction—up to 72%—in healthy volunteer studies, with favorable safety and tolerability. SKY-0515 is currently being evaluated in a Phase 2/3 clinical trial. About Skyhawk TherapeuticsSkyhawk Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule therapies designed to modulate critical RNA targets and revolutionize patient treatment for some of the world's most intractable diseases. Skyhawk's discovery expertise is rooted in its proprietary drug discovery platform, which assesses, identifies, and tests RNA splicing targets and small molecules across a broad range of therapeutic areas and disease states. Skyhawk has built collaborations with multiple pharma partners that leverage Skyhawk's novel platform across disease areas including neurodegenerative disease, autoimmune disease, and oncology. For more information visit Skyhawk ContactsKyle Dow, VP Corporate Logo - View original content: SOURCE Skyhawk Therapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
34 minutes ago
- Business Wire
Miso and Roboworx Team to Deliver Comprehensive Restaurant Automation Solutions
LOS ANGELES & CHICAGO--(BUSINESS WIRE)--Miso, a leader in restaurant technology and AI kitchen automation, has signed robot field service organization Roboworx to provide installation, maintenance and ongoing support for Miso's restaurant automation systems. This collaboration combines Miso's cutting-edge AI-powered Flippy Fry Station robots with Roboworx's nationwide network of robot technicians to provide restaurant operators with a complete, powerful and reliable solution, and a rapid return on investment (ROI). Robot field service specialist #Roboworx announces a new partnership with #restauranttech & #AI kitchen #automation leader @misorobotics to install, maintain & support #Flippy, Miso's signature restaurant automation system. #FoodTech #FlippyFryStation Share With the restaurant industry facing persistent labor shortages and operational challenges, automation has become essential for improving efficiency, reducing food waste, and enhancing customer satisfaction. Flippy Fry Station, powered by Miso's proprietary Kitchen AI, delivers 99% uptime with 'self-healing' capabilities. The robots automate the undesirable and hazardous tasks of cooking fried foods such as French fries, onion rings, chicken, and tacos with precision and consistency. Additionally, Flippy creates safer work environments and expands labor flexibility because the robot can be operated by employees under age 18 in compliance with federal regulations. 'Our goal at Miso is to deliver 'day one ROI' to our customers through reliable, intelligent automation,' said Rebecca Davis, VP of Operations, Miso Robotics. 'To scale effectively, we needed a service partner with deep robotics expertise and a national reach. Roboworx's proven track record and technical expertise make it the ideal partner to ensure our systems are deployed and maintained to the highest standard.' Miso's robotics-as-a-service (RaaS) model offers Flippy Fry Stations with no upfront costs and a monthly fee that is often less than the cost of a full-time employee. Flippy Fry Stations are currently deployed in 20 locations, including Jack in the Box and White Castle restaurants, with weekly deployments scheduled through the end of September. Rollout plans leverage Roboworx for both new installations and installed base Under the agreement with Miso, Roboworx will support both new installations and the existing installed base of Flippy Fry Stations. Roboworx's field service technicians will lead deployments, conduct preventative maintenance, provide on-demand service, and perform regular customer success check-ins, ensuring each system delivers maximum value. The collaboration allows Miso to focus on advancing its technology, while Roboworx ensures operational excellence in the field. 'Miso's automation platform is powerful and intuitive, but like any sophisticated systems, it requires knowledgeable support to deliver its full potential,' said Jeff Pittelkow, managing director, Roboworx. 'As the service backbone of Miso's nationwide rollout, we're helping the company set a new standard for restaurant automation – and helping it and its customers thrive.' About Miso Miso is a pioneer in kitchen automation and AI-driven robotics in the restaurant and food service industries. Its flagship product, Flippy Fry Station, automates the frying process with unmatched precision and consistency. Powered by Miso's proprietary Kitchen AI, Miso's technology is reshaping kitchen operations, addressing labor challenges, and enabling more efficient food preparation in partnership with leading brands and innovators. Learn more at Press & Media resources can be found at About Roboworx Roboworx offers world-class robot service, maintenance, and management, delivered by expert technicians, to ensure that both robot OEMs and end customers maximize the value of their robot fleets. Roboworx's comprehensive services include preventive maintenance, on-call break/fix, installation, customer training & retraining, and warehousing/depot services. The company caters to a wide variety of robots across numerous industries, including warehousing, cleaning, delivery, security, and more. Roboworx' services are available through flexible subscription or pay-as-you-go programs, tailored to meet the unique needs of each partnership. For more information, visit
